Bottom line
A marketed three-component research-peptide combination (GHK-Cu, BPC-157, TB-500) sold as a single lyophilised vial under the name "GLOW." Composition ratios vary by vendor and batch. There is no published peer-reviewed study of this exact three-component combination. Each component has independent preclinical evidence; combination-specific synergy is theoretical.
No established or recommended human dose.
Name and formulation variability
"GLOW" is a vendor-coined marketing name. No pharmacopoeial or regulatory standard exists. Observed formulations:
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Legion Peptides (2026) | GHK-Cu, BPC-157, TB-500 | 50 / 10 / 10 mg (70 mg total) | Vendor-declared; unverified purity claims |
| Skye Peptides batch GLOW25-40-004 (2026) | GHK-Cu, BPC-157, TB-500 | 33.8 / 6.7 / 10.7 mg | Vendor-supplied; unverified |
| Skye Peptides batch GLOW25-70-005 (2026) | GHK-Cu, BPC-157, TB-500 | 60.4 / 11.0 / 10.4 mg | Vendor-supplied; unverified |
| Durham Peptides (2026) | GHK-Cu, BPC-157, TB-500 | 50 / 10 / 10 mg | Vendor-declared; unverified |
| D&L Peptides (2026) | GHK-Cu, BPC-157, TB-500 | 50 / 10 / 10 mg | Vendor-declared |
| Aventris Labs (2026) | GHK-Cu, BPC-157, TB-500 | 50 / 10 / 10 mg | Vendor-declared; unverified |
Ratios vary: GHK-Cu ranges from ~33.8 to ~62 mg; BPC-157 from ~6.7 to ~11.9 mg; TB-500 from ~10.4 to ~10.7 mg across observed batches. No standard formulation exists.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| GHK-Cu | Endogenous copper tripeptide; modulates collagen/elastin synthesis, antioxidant gene expression, MMP activity | None in published literature for this specific triple combination | Co-lyophilisation stability claimed by vendors; no independent published stability study |
| BPC-157 | Synthetic 15-AA pentadecapeptide; preclinical studies on VEGFR2/NO-mediated angiogenesis, GI protection, tendon repair | None in published literature for this specific triple combination | No published data on interaction with GHK-Cu or TB-500 in solution |
| TB-500 | Synthetic thymosin beta-4 fragment (43 AA or 7-AA LKKTETQ fragment); actin sequestration, cell migration | None in published literature for this specific triple combination | TB-500 molecular-weight ambiguity (4,963 vs ~890 Da) complicates ratio analysis |
Combination-specific studies
No published peer-reviewed study tests the specific GHK-Cu + BPC-157 + TB-500 triple combination against individual components or placebo. The combination rationale is mechanistic extrapolation: GHK-Cu for matrix remodelling, BPC-157 for angiogenesis, TB-500 for cell migration.
Safety and interaction uncertainties
No combination-specific toxicology data
GHK-Cu imparts a blue colour to the lyophilised powder that may interfere with visual inspection
Co-reconstitution stability in bacteriostatic water has not been independently characterised
Individual component safety profiles (preclinical only) do not predict combination safety
Regulatory and product-quality notes
None of the three components is FDA-approved for any therapeutic indication
All are sold as "research use only" products outside pharmaceutical regulation
WADA: BPC-157 is listed under S0; thymosin-β4 and derivatives such as TB-500 are listed under S2.3. GHK-Cu is not explicitly named in the 2026 List, so its status should not be inferred from this marketed blend name.
Purity claims are unverified vendor or test-provider reports and have not been independently corroborated
Evidence gaps
No controlled study of the triple combination
No pharmacokinetic study of combined administration
No stability study of co-lyophilised or co-reconstituted material
No human clinical data for any of the three components for tissue-repair claims
Sources
Legion Peptides. GLOW70 product page. https://legionpeptides.com/multi-peptide-blends/glow/ accessed 2026-08-06.
Skye Peptides. GLOW GHK-Cu / TB-500 / BPC-157 product page. https://skyepeptidesltd.com/product/glow-ghk-cu-tb-500-bpc-157/ accessed 2026-08-06.
Durham Peptides. GLOW Blend Composition. https://www.durhampeptides.ca/post/glow-blend-composition accessed 2026-08-06.
Aventris Labs. GLOW Blend product page. https://aventrislabs.com/product/glow-blend-bpc-157-tb-500-ghk-cu-70mg/ accessed 2026-08-06.
D&L Peptides. GLOW Research Blend. https://dlpeptides.com/peptides/glow-peptide/ accessed 2026-08-06.
Miro Biotech. GLOW Blend. https://www.mirobiotech.com/products/glow accessed 2026-08-06.
World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf